石药集团(01093):SYS6052(重组带状疱疹病毒疫苗(CHO细胞))的I/II期临床试验在中国正式启动

智通财经
Nov 02

智通财经APP讯,石药集团(01093)发布公告,本集团开发的SYS6052重组带状疱疹病毒疫苗(中国仓鼠卵巢(CHO)细胞)的I/II期临床试验已在中国正式启动。

该产品是本集团研发的重组蛋白疫苗产品,由水痘-带状疱疹病毒糖蛋白E(gE)蛋白抗塬与本集团自主开发的新型纳米佐剂系统构成。通过优化抗原和纳米佐剂系统,该产品可诱导较强的体液免疫和细胞免疫应答。

本集团于2026年7月收到中华人民共和国国家药品监督管理局签发的《药物临床试验批准通知书》,并于获批后启动一项随机、盲法、对照的I/II期临床试验,旨在评价该产品在40岁及以上人群中接种的安全性及免疫塬性。目前,该临床试验的参与者招募和筛选工作正在积极推进中。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10